Healx, a pioneer in AI-powered drug discovery for rare and neglected conditions, has partnered with SCI Ventures - the world’s first specialist venture fund focused on curing paralysis- to accelerate ...

AI has been a buzzword in the pharmaceutical industry for almost a decade, with countless headlines promising to ...

XtalPi (2228.HK), a leading global technology company in integrating artificial intelligence (AI) and robotics to advance the ...

Drug discovery has traditionally been slow, expensive and prone to failure, but AI and machine learning are set to change all ...

Scientists at Shaanxi Normal University have developed an AI-powered dual-channel model that predicts miRNA–drug interactions with up to 96% ...

Despite longstanding reliance on sputum smear microscopy, culture methods, and chest X-rays, conventional TB diagnostics ...

XtalPi has accrued a number of Big Pharma partners over the years, including Eli Lilly, which struck a $250 million deal in 2023 to use XtalPi’s tech to identify potential drug candidates that Lilly ...

ResearchAndMarkets projects the AI medical diagnostics market to surge to $46.59 billion by 2034, driven by a blistering 33.72% CAGR. Private equity firms believe 2025 could eclipse 2024 as the ...

Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other ...

Symbiotic.blue, a biotech looking to build an AI-driven drug discovery platform, has begun a pre-seed funding round.

The Global AI in Drug Discovery and Development Market is expected to reach at a CAGR of 18.5% during the forecast period 2025-2033. The AI in Drug Discovery and Development Market is expanding ...